• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hyperparathyroidism Following Denosumab and Zoledronate Therapy in a Secondary Care Setting.

作者信息

Kotecha Jalpa, Fardeen Kazi Mashfia, Mirzazadeh Mehdi

机构信息

From the King's College Hospital, London.

St Helier Hospital, Carshalton, England.

出版信息

J Clin Rheumatol. 2023 Mar 1;29(2):101-104. doi: 10.1097/RHU.0000000000001894. Epub 2022 Aug 18.

DOI:10.1097/RHU.0000000000001894
PMID:35981297
Abstract
摘要

相似文献

1
Hyperparathyroidism Following Denosumab and Zoledronate Therapy in a Secondary Care Setting.
J Clin Rheumatol. 2023 Mar 1;29(2):101-104. doi: 10.1097/RHU.0000000000001894. Epub 2022 Aug 18.
2
Effects of zoledronate on bone mineral density and bone turnover after long-term denosumab therapy: Observations in a real-world setting.唑来膦酸对长期地舒单抗治疗后骨密度和骨转换的影响：真实世界观察。
Bone. 2022 Oct;163:116498. doi: 10.1016/j.bone.2022.116498. Epub 2022 Jul 23.
3
The Duration of Denosumab Treatment and the Efficacy of Zoledronate to Preserve Bone Mineral Density After Its Discontinuation.地舒单抗治疗持续时间和唑来膦酸在停药后维持骨密度的疗效。
J Clin Endocrinol Metab. 2021 Sep 27;106(10):e4155-e4162. doi: 10.1210/clinem/dgab321.
4
The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis.唑来膦酸单次输注对绝经后骨质疏松症女性停用地舒单抗后骨密度和骨转换标志物的三年影响。
Bone. 2020 Sep;138:115478. doi: 10.1016/j.bone.2020.115478. Epub 2020 Jun 11.
5
The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis.唑来膦酸单次输注对绝经后骨质疏松症女性停用地舒单抗后骨密度的 5 年影响。
Calcif Tissue Int. 2023 Oct;113(4):469-473. doi: 10.1007/s00223-023-01119-7. Epub 2023 Aug 3.
6
Effect of Zoledronate on Bone Loss After Romosozumab/Denosumab: 2-Year Follow-up.唑来膦酸对罗莫单抗/地诺单抗治疗后骨质流失的影响：2年随访
Calcif Tissue Int. 2019 Jul;105(1):107-108. doi: 10.1007/s00223-019-00553-w. Epub 2019 Apr 17.
7
Circulating sclerostin levels during denosumab discontinuation and the subsequent early or late zoledronate infusion.在狄诺塞麦停药期间以及随后早期或晚期输注唑来膦酸过程中循环骨硬化蛋白水平。
Endocrine. 2021 Jul;73(1):223-225. doi: 10.1007/s12020-021-02666-5. Epub 2021 Mar 2.
8
Bone Mass Gains After One Denosumab Injection Followed by Zoledronate.注射地舒单抗一次后接着用唑来膦酸治疗可增加骨量。
J Clin Densitom. 2022 Jul-Sep;25(3):293-298. doi: 10.1016/j.jocd.2022.03.001. Epub 2022 Mar 24.
9
A Single Infusion of Zoledronate in Postmenopausal Women Following Denosumab Discontinuation Results in Partial Conservation of Bone Mass Gains.唑来膦酸单次输注可部分保留绝经后妇女停用地舒单抗后的骨量获益。
J Bone Miner Res. 2020 Jul;35(7):1207-1215. doi: 10.1002/jbmr.3962. Epub 2020 Feb 11.
10
Comparative Effect of Zoledronate at 6 Versus 18 Months Following Denosumab Discontinuation.唑来膦酸在停用地舒单抗 6 个月与 18 个月后的比较疗效。
Calcif Tissue Int. 2021 May;108(5):587-594. doi: 10.1007/s00223-020-00785-1. Epub 2021 Jan 2.